Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.40 |
| ▸ | FNTB | P49356 | 9/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760842 | 0.96 | CYP11B1 (0.41) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL6759290 | 0.94 | CYP11B1 (0.41) | FNTAFNTBCYP11B1CYP11B2KCNH2 | |
| SCHEMBL6760840 | 0.94 | CYP11B1 (0.40) | FNTAFNTBCYP11B1CYP11B2KCNH2 | |
| SCHEMBL6674273 | 0.90 | CYP11B1 (0.39) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL6757437 | 0.90 | CYP11B1 (0.42) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL6602097 | 0.90 | CYP11B1 (0.42) | FNTAFNTBCYP11B1CYP11B2KCNH2 | |
| SCHEMBL6757414 | 0.89 | FNTA (0.40) | FNTAFNTBCYP11B1CYP11B2KCNH2 | |
| SCHEMBL6600292 | 0.89 | CYP11B1 (0.41) | FNTAFNTBCYP11B1CYP11B2KCNH2 | |
| SCHEMBL6756396 | 0.88 | FNTA (0.41) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL6757376 | 0.87 | FNTA (0.41) | FNTAFNTBCYP11B1CYP11B2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | PIERRE FABRE MEDICAMENT (FR) | 2004-10-14 | — | — | US | claimed |
| EP-1395581-A2 | NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, PREPARATION AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS | PIERRE FABRE MEDICAMENT (FR) | 2004-03-10 | — | — | EP | claimed |
| WO-2002098852-A2 | NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS | PIERRE FABRE MEDICAMENT (FR) | 2002-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | CBR1, CBR3, HCCS | FNTA 338/4885FNTB 215/4885CYP11B1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.